Nam Eun Ji, Yoon Heejei, Kim Sang Wun, Kim Hoguen, Kim Young Tae, Kim Jae Hoon, Kim Jae Wook, Kim Sunghoon
Women's Cancer Clinic, Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea.
Clin Cancer Res. 2008 May 1;14(9):2690-5. doi: 10.1158/1078-0432.CCR-07-1731.
Although microRNAs have recently been recognized as riboregulators of gene expression, little is known about microRNA expression profiles in serous ovarian carcinoma. We assessed the expression of microRNA and the association between microRNA expression and the prognosis of serous ovarian carcinoma.
Twenty patients diagnosed with serous ovarian carcinoma and eight patients treated for benign uterine disease between December 2000 and September 2003 were enrolled in this study. The microRNA expression profiles were examined using DNA microarray and Northern blot analyses.
Several microRNAs were differentially expressed in serous ovarian carcinoma compared with normal ovarian tissues, including miR-21, miR-125a, miR-125b, miR-100, miR-145, miR-16, and miR-99a, which were each differentially expressed in >16 patients. In addition, the expression levels of some microRNAs were correlated with the survival in patients with serous ovarian carcinoma. Higher expression of miR-200, miR-141, miR-18a, miR-93, and miR-429, and lower expression of let-7b, and miR-199a were significantly correlated with a poor prognosis (P < 0.05).
Our results indicate that dysregulation of microRNAs is involved in ovarian carcinogenesis and associated with the prognosis of serous ovarian carcinoma.
尽管微小RNA最近已被公认为基因表达的核糖调节因子，但对于浆液性卵巢癌中的微小RNA表达谱却知之甚少。我们评估了微小RNA的表达以及微小RNA表达与浆液性卵巢癌预后之间的关联。
本研究纳入了2000年12月至2003年9月期间诊断为浆液性卵巢癌的20例患者以及因良性子宫疾病接受治疗的8例患者。使用DNA微阵列和Northern印迹分析检测微小RNA表达谱。
与正常卵巢组织相比，浆液性卵巢癌中有几种微小RNA差异表达，包括miR-21、miR-125a、miR-125b、miR-100、miR-145、miR-16和miR-99a，它们在超过16例患者中均有差异表达。此外，一些微小RNA的表达水平与浆液性卵巢癌患者的生存相关。miR-200、miR-141、miR-18a、miR-93和miR-429的高表达以及let-7b和miR-199a的低表达与不良预后显著相关（P<0.05）。
我们的结果表明，微小RNA的失调参与了卵巢癌的发生，并与浆液性卵巢癌的预后相关。
